PDUFA, Biosimilar Application Fees To Rise 10.7%; FDA’s Workload Adjuster Needs Work
This article was originally published in The Pink Sheet Daily
Facility and product user fees will increase by more than 5% for fiscal year 2014; FDA calculated the fees using a revised workload adjuster because the previous method failed to reflect increasing complexity of the drug review process.
You may also be interested in...
FDA tells industry that proposal on trials also can’t use SPA-like process.
Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.
Agency announces new prescription drug, generic drug and biosimilar rates – with one fee increasing more than 47%.